Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2014BloodOpen Access

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

View Full Paper
Ask AI
Bookmark
Share

Authors

RBRafael BejarUC San Diego Health SystemALAllegra M. LordSomerville HospitalKSKristen E. StevensonBoston University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bejar et al. (2014) studied this question.

synapsesocial.com/papers/69dffb672833447a7e255d3bhttps://doi.org/10.1182/blood-2014-06-582809
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine2008 · 974 citations
  2. 2Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial2009 · 317 citations
  3. 3Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion2006 · 1,329 citations
  4. 4Clinical and biological implications of driver mutations in myelodysplastic syndromes2013 · 1,869 citations